Colorectal Cancer in Europe & Central Asia
Death rates for Colorectal Cancer across 58 countries in Europe & Central Asia.
| # | Country | Rate |
|---|
Colorectal cancer is the third most commonly diagnosed cancer globally and the second leading cause of cancer death, claiming approximately 935,000 lives annually. Incidence has historically been highest in high-income countries, but rates are rising rapidly in transitioning economies as populations adopt Western dietary patterns — high in red and processed meat, low in fibre — combined with increased obesity and physical inactivity. Genetic predisposition plays a role in 5-10% of cases (Lynch syndrome, familial adenomatous polyposis), but the majority are sporadic. Most colorectal cancers develop from precancerous polyps over 10-15 years, creating a wide window for screening and prevention. Five-year survival exceeds 90% for localized disease but falls below 15% for distant metastases, underscoring the importance of early detection. There is also a concerning global trend of increasing colorectal cancer incidence in adults under 50. Europe and Central Asia benefit from relatively strong health systems and high physician density, but face ageing populations, rising non-communicable disease burdens, and persistent East-West health outcome gradients. In Europe & Central Asia, colorectal cancer mortality is near global averages, though the region exhibits a marked gradient between Western European countries with low rates and Central Asian nations facing higher burdens.
Colonoscopy screening with polypectomy can prevent colorectal cancer by removing precancerous polyps before they become malignant, reducing both incidence and mortality. Faecal immunochemical testing (FIT) and stool DNA tests offer non-invasive screening alternatives. Modifiable risk reduction includes maintaining a healthy body weight, regular physical activity, limiting red and processed meat consumption, adequate fibre intake, moderating alcohol use, and avoiding tobacco. Aspirin chemoprevention is recommended for certain high-risk individuals. For Lynch syndrome carriers, intensified surveillance and consideration of prophylactic surgery reduce cancer risk substantially.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for colorectal cancer in Europe & Central Asia, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Cancer mortality data combine information from population-based cancer registries, vital registration systems, and statistical modeling where direct data are sparse. Incidence-to-mortality ratios and survival estimates help distinguish regions where high death rates stem from high incidence versus those where limited access to early detection and treatment drives poor outcomes. For colorectal cancer across Europe & Central Asia, comparing mortality rates alongside screening coverage and treatment availability provides crucial context for understanding regional disparities.